(Q41865617)

13 October 2017

Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin (English)

1 reference

13 October 2017

N Duval

1

1 reference

13 October 2017

C Lunven

2

1 reference

13 October 2017

D P O'Brien

3

1 reference

13 October 2017

A Grosset

4

1 reference

13 October 2017

S E O'Connor

5

1 reference

13 October 2017

C N Berry

6

1 reference

13 October 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

British Journal of Pharmacology

13 October 2017

1 reference

13 October 2017

118

1 reference

13 October 2017

3

1 reference

13 October 2017

727-733

1 reference

Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Angioscopic Evaluation of Coronary-Artery Thrombi in Acute Coronary Syndromes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1909704

Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4

5 June 2018

1 reference

12 December 2020

Combined administration of aspirin and a specific thrombin inhibitor in man

1 reference

12 December 2020

Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion

1 reference

12 December 2020

Comparative study on heparin and a synthetic thrombin inhibitor no. 805 (MD-805*) in experimental antithrombin III-deficient animals

1 reference

12 December 2020

Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries

1 reference

12 December 2020

The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries

1 reference

12 December 2020

Thrombin-induced vasoconstriction in isolated cerebral arteries and the influence of a synthetic thrombin inhibitor

1 reference

12 December 2020

Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis

1 reference

12 December 2020

Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis

1 reference

12 December 2020

In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor

1 reference

12 December 2020

Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis

1 reference

12 December 2020

Persistent activation of coagulation mechanism in unstable angina and myocardial infarction

1 reference

12 December 2020

Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin

1 reference

12 December 2020

Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis

1 reference

12 December 2020

Properties of the factor Xa binding site on human platelets

1 reference

12 December 2020

10.1111/J.1476-5381.1996.TB15460.X

Identifiers

DOI

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

8762100

1 reference